These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 3294920)

  • 1. Tiaspirone in schizophrenia.
    Moore NC; Meyendorff E; Yeragani V; LeWitt PA; Gershon S
    J Clin Psychopharmacol; 1987 Apr; 7(2):98-101. PubMed ID: 3294920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled clinical trial of tiaspirone in schizophrenia.
    Jain AK; Kelwala S; Moore N; Gershon S
    Int Clin Psychopharmacol; 1987 Apr; 2(2):129-33. PubMed ID: 2885367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of antipsychotic activity of an unique agent: SU-23397.
    Mielke EH; Gallant DM; Bishop G; Kessler CM
    Psychopharmacol Commun; 1975; 1(2):117-22. PubMed ID: 4858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical trial of a structurally unique neuroleptic (SU-23397).
    Angrist BM; Sathananthan G; Thompson H; Gershon S
    Curr Ther Res Clin Exp; 1975 Aug; 18(2):359-63. PubMed ID: 809249
    [No Abstract]   [Full Text] [Related]  

  • 8. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC; Lung FW; Chong MY
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The depot compounds moditen (fluphenazine) and IMAP (fluspirilene) in clinical practice.
    Faltus F
    Act Nerv Super (Praha); 1974 Aug; 16(3):167-8. PubMed ID: 4607824
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation.
    Chouinard G; Annable L; Steinberg S
    J Clin Psychopharmacol; 1986 Feb; 6(1):21-6. PubMed ID: 3512622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China.
    Xiang YT; Weng YZ; Leung CM; Tang WK; Ungvari GS; Gerevich J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):756-60. PubMed ID: 17289236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risks of atypical antipsychotic drug treatment.
    Drici MD; Priori S
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of clinical usefulness of decaldol (haloperidol decanoate) produced by WZF Polfa in Warsaw in long-term treatment of schizophrenia].
    Morasiewicz J; Baranowski P; Borys J; Jańska-Skomorowska M; Kiejna A
    Psychiatr Pol; 1995; 29(3):405-20. PubMed ID: 7652093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men.
    Kleinbloesem CH; Jaquet-Müller F; al-Hamdan Y; Baldauf C; Gisclon L; Wesnes K; Curtin CR; Stubbs RJ; Walker SA; Brunner-Ferber F
    Clin Pharmacol Ther; 1996 Jun; 59(6):675-85. PubMed ID: 8681493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.